Biological E (BioE) and European biotech company Valneva SE on Monday said the World Health Organization (WHO) has pre-qualified its Japanese Encephalitis vaccine for global use in adults. The company expects that the paediatric indication will also be prequalified by the end of 2013.
The WHO prequalification was a key step for distribution of the vaccine in developing countries. “We are happy that our JE vaccine is the first ever WHO prequalified vaccine. It is an extremely important achievement for the vaccines community as our vaccine’s prequalification is well in time to support GAVI’s plans of introducing the JE vaccine in several developing countries,” said Mahima Datla, MD, BioE.
BioE and Valneva have joined hands in partnership in 2005 for the development and commercialization of a Japanese Encephalitis vaccine for endemic regions, based on Valneva’s JEV technology. The vaccine is being marketed in India under the trade-name JEEV and commercialization in other JE-endemic countries is planned.